From Bladder Cancer to Global Immunotherapy Platform从膀胱癌到全球免疫治疗平台
Varsity Tech Research — February 2026
First and only IL-15 receptor agonist approved in oncology.全球首个也是唯一获批的肿瘤 IL-15 受体激动剂。
Nogapendekin alfa inbakicept
First-in-class IL-15 receptor superagonist
FDA Approved April 2024: ANKTIVA + BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CIS
First and only IL-15 receptor agonist approved in oncology worldwide
Nogapendekin alfa inbakicept
全球首创 IL-15 受体超级激动剂
FDA 2024年4月批准：ANKTIVA + BCG 治疗 BCG 无应答的非肌层浸润性膀胱癌 (NMIBC) 伴原位癌
全球首个也是唯一获批用于肿瘤学的 IL-15 受体激动剂
Dr. Patrick Soon-Shiong
Billionaire physician & surgeon
Owner of the Los Angeles Times
Pioneered Abraxane (blockbuster cancer drug acquired by Celgene)
Visionary but controversial figure — STAT News investigations on claims and governance
陈颂雄博士
亿万富翁医师和外科医生
《洛杉矶时报》所有者
开创了 Abraxane（被 Celgene 收购的重磅抗癌药物）
富有远见但有争议的人物 — STAT News 对其声明和治理的调查报道
From one FDA approval to 33 countries in under 2 years.不到两年时间，从一项 FDA 批准扩展至 33 个国家。
From $14.75M to $113M in a single year.一年内从 1475万美元增长至 1.13亿美元。
~99% gross margins offset by heavy cash burn and significant debt.约 99% 的毛利率被大量现金消耗和巨额债务所抵消。
Oberland RIPA: $320M revenue interest purchase agreement
Nant Capital Notes: $505M (related-party)
Negative equity: -$523M
Oberland RIPA：3.2亿美元收入利息购买协议
Nant Capital 票据：5.05亿美元 (关联方)
负净资产：-5.23亿美元
Burn: ~$60-65M/quarter
Runway: 3-4 quarters at current rate
SG&A down 11.2% YoY — cost discipline improving
Shares outstanding: ~985M
消耗：每季度约 6000-6500万美元
现金跑道：按当前消耗率约 3-4个季度
SG&A 同比下降 11.2% — 成本控制改善
流通股数：约 9.85亿股
86x P/S on a negative equity company — priced for blockbuster multi-indication success.负净资产公司的 86 倍市销率 — 估值已反映重磅多适应症成功预期。
Cash/share: ~$0.25
Price: $9.83
Price/Cash: ~39x
The stock price reflects massive future expectations, not current fundamentals.
每股现金：约 $0.25
股价：$9.83
股价/现金：约 39 倍
股价反映的是巨大的未来预期，而非当前基本面。
Merck (Keytruda): Mega-cap, dominant IO franchise
BMS (Opdivo): Similar scale, diversified
IBRX trades at a premium relative to revenue, but if ANKTIVA becomes a multi-indication platform, current valuation could eventually be justified.
默克 (Keytruda)：超大市值，主导 IO 领域
BMS (Opdivo)：类似规模，产品线多元
IBRX 相对收入交易溢价极高，但若 ANKTIVA 成为多适应症平台，当前估值最终可能获得合理化。
6 catalysts that could drive transformational upside.六大催化剂可能带来变革性上行空间。
Massive TAM expansion — 30+ countries, new revenue streams巨大的市场扩展 — 30+国家，新收入来源
Saudi approval = proof of concept; US/EU approval would be transformational沙特批准 = 概念验证；美国/欧盟批准将是变革性的
QUILT-88 trial complete; RMAT designation (fast-track to approval)QUILT-88 试验完成；RMAT 认定（快速审批通道）
Resubmission path being discussed with FDA — expands bladder cancer TAM正与 FDA 讨论重新提交路径 — 扩大膀胱癌市场
Positions ANKTIVA as a platform therapy across solid tumors将 ANKTIVA 定位为实体瘤平台级治疗
Analysts project ~52% annual growth going forward; EU launch amplifies分析师预计未来年增长约 52%；欧盟上市将进一步放大
ANKTIVA expanding into multiple high-value oncology indications.ANKTIVA 正扩展至多个高价值肿瘤适应症。
Papillary Bladder Cancer — FDA resubmission path under discussion; would further expand the bladder cancer franchise.乳头状膀胱癌 — 正与 FDA 讨论重新提交路径；将进一步扩大膀胱癌产品线。
Up ~430% from 52-week low. Well above all moving averages.较52周低点上涨约 430%。远高于所有移动平均线。
$7.75 (recent support) • $5.51 (major support)$7.75（近期支撑）• $5.51（主要支撑）
$10.23 → $11.00 (52-wk high)
WARNING: Sharp pullbacks likely$10.23 → $11.00（52周高点）
警告：大幅回调可能性大
8 material risks investors must weigh.投资者必须权衡的 8 大实质性风险。
3-4 quarters at current burn — dilution or capital raise likely in 2026按当前消耗率仅余3-4个季度 — 2026年可能稀释或融资
STAT News investigations on Soon-Shiong's claims and practicesSTAT News 对陈颂雄声明和做法的调查报道
Complex related-party transactions with Nant Capital ($505M notes)与 Nant Capital 的复杂关联方交易（5.05亿美元票据）
All revenue from ANKTIVA in one indication (bladder cancer)所有收入来自 ANKTIVA 的单一适应症（膀胱癌）
Merck Keytruda, BMS Opdivo, Roche Tecentriq — massive IO incumbents默克 Keytruda、BMS Opdivo、罗氏 Tecentriq — 巨型 IO 巨头
86x P/S on a negative equity company — priced beyond perfection负净资产公司的 86 倍市销率 — 估值超越完美预期
4 sales, 0 purchases in past 6 months — zero insider conviction过去6个月内 4 笔卖出、0 笔买入 — 内部人零信心
~985M shares outstanding and growing — further dilution near certain约 9.85 亿流通股且持续增长 — 进一步稀释几乎确定
IBRX vs. major immunotherapy players — small but differentiated.IBRX 对比主要免疫治疗公司 — 规模小但差异化。
| Company公司 | Drug药物 | Mechanism机制 | Scale规模 | Edge优势 |
|---|---|---|---|---|
| Merck | Keytruda | PD-1 | $25B+ rev250亿+收入 | Dominant IO leader, massive infrastructureIO 领导者，庞大基础设施 |
| BMS | Opdivo | PD-1 | $9B+ rev90亿+收入 | Diversified portfolio, global reach多元化产品组合，全球覆盖 |
| Roche | Tecentriq | PD-L1 | $3B+ rev30亿+收入 | Established combo therapies成熟的联合疗法 |
| ImmunityBio | ANKTIVA | IL-15 | $113M rev1.13亿收入 | Unique mechanism, fastest growing独特机制，增长最快 |
Key Differentiator: ANKTIVA uses a unique IL-15 mechanism (innate immune activation) vs. PD-1/PD-L1 checkpoint inhibitors — complementary, not competitive. Potential for combination with existing IO therapies.核心差异：ANKTIVA 使用独特的 IL-15 机制（先天免疫激活），对比 PD-1/PD-L1 检查点抑制剂 — 互补而非竞争。有与现有 IO 疗法联合使用的潜力。
5 analysts covering — wide range of price targets reflecting uncertainty.5位分析师覆盖 — 目标价范围较广，反映高度不确定性。
Current price $9.83: below bull targets, above bear target. Consensus: Strong Buy (5 analysts).当前股价 $9.83：低于看涨目标，高于看跌目标。共识：强烈买入（5位分析师）。
Three scenarios — next 2-3 quarters will be defining.三种情景 — 未来 2-3 个季度将是关键。
NSCLC + Pancreatic approvals
Multi-bagger from here
Probability: Medium-LowNSCLC + 胰腺癌获批
多倍收益潜力
概率：中低
Continued bladder cancer growth
EU ramp + stable operations
Probability: Medium膀胱癌业务持续增长
欧盟放量 + 稳定运营
概率：中等
Cash crunch + dilution
Trial failures + sentiment collapse
Probability: Medium现金危机 + 稀释
试验失败 + 情绪崩溃
概率：中等
Key Decision Point: Next 2-3 quarters will be defining — NSCLC data readouts, cash position updates, and EU launch execution.关键决策点：未来 2-3 个季度将是决定性的 — NSCLC 数据读出、现金状况更新以及欧盟上市执行情况。
Genuine commercial traction meets extreme risk.真实的商业牵引力遇上极端风险。
✔ 700% revenue growth — genuine traction
✔ 33-country commercial footprint
✔ ~99% gross margins (biologics)
✔ NSCLC & pancreatic cancer pipeline
✔ Unique IL-15 mechanism (first-in-class)
✔ EU Commission approval unlocks massive TAM
✔ 收入增长 700% — 真实的商业牵引力
✔ 33国商业布局
✔ 约 99% 毛利率（生物制品）
✔ NSCLC 和胰腺癌管线
✔ 独特的 IL-15 机制（全球首创）
✔ 欧盟批准解锁巨大市场空间
✘ Parabolically extended (+430% from lows)
✘ 86x P/S — extreme valuation
✘ 3-4 quarter cash runway, dilution likely
✘ Credibility & governance concerns
✘ Zero insider buying (4 sales, 0 purchases)
✘ Single product, single approved indication
✘ 抛物线式上涨（较低点 +430%）
✘ 86 倍市销率 — 极端估值
✘ 现金跑道仅 3-4 季度，可能稀释
✘ 信誉和治理风险
✘ 内部人零买入（4笔卖出，0笔买入）
✘ 单一产品，单一获批适应症
"This is SPECULATION, not investment. If you're in, trade it — don't marry it.""这是投机，不是投资。如果参与，当作交易对待 — 不要死守。"
Protect with tight stops below $7.75 support.在 $7.75 支撑位下方设置严格止损保护。
The information presented in this deck is for educational and research purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. Always do your own due diligence and consult a licensed financial advisor before making investment decisions. 本报告中的信息仅供教育和研究目的使用。不构成财务建议、投资推荐或买卖任何证券的要约。过往业绩不代表未来表现。所有投资都存在风险，包括本金损失的可能性。在做出投资决策之前，请务必进行自己的尽职调查并咨询持牌财务顾问。
Varsity TechVarsity Tech
AI-Native Quantitative Trading PlatformAI 原生量化交易平台
← View All Research Decks← 查看所有研究报告Varsity Tech Research — February 2026